Eyenovia Announces Closing of $50 Million Private Placement, Successful Accumulation of More Than One Million HYPE Tokens, and Update on its Optejet Development Program
The significant HYPE token position, acquired at an average price of approximately $34 per token, makes Eyenovia the first Nasdaq listed company to run a validator on Hyperliquid
FDA registration of the Optejet User Filled Device (UFD) on track for September 2025; meaningful partnering discussions ongoing
LAGUNA HILLS, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced the closing of its previously announced $50 million private placement (PIPE) with accredited investors.
The PIPE Financing enabled the Company to acquire 1,040,584.5 HYPE at an average price of approximately $34 per token. As part of the strategy, the Company also intends to initiate its own network validator alongside an ecosystem partner, which will support the liveness of the Hyperliquid blockchain and lay the foundation for accessing HYPE staking yield.
Michael Rowe, Chief Executive Officer of Eyenovia, stated, "The closing of this transformational financing is the first step in the execution of our new cryptocurrency treasury reserve strategy. We believe this initiative will create long-term value for our shareholders by capitalizing on the growing adoption of digital currencies and the accelerating pace of related innovation. At the same time, we remain sharply focused on efficiently completing the remaining development steps in support of FDA registration of the Optejet UFD."
"The steps we are taking are intended to provide the best vehicle for retail and institutional investors to access HYPE and its native yield in a secure, custodied environment," said Hyunsu Jung, Chief Investment Officer of Eyenovia. "The Company's successful purchase of our initial HYPE position paves the way for deeper engagement in the Hyperliquid ecosystem."
Chardan acted as the sole placement agent in connection with the transaction.
Pending Board approval in the coming days, Eyenovia is expected to change its name and ticker to "Hyperion DeFi" and "HYPD," respectively.
Optejet Development UpdateDevelopment of the Optejet UFD continues to progress according to the Company's projected timelines, with verification and validation activities expected to commence next month. Eyenovia remains on track to register the device with the FDA in September of this year.
The Company has initiated dialogue with ...
